Company Overview of NeOnc Technologies, Inc.
NeOnc Technologies, Inc., a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. It offers NEO100, a purified form of the natural compound perillyl alcohol (POH); NEO102, an isoform of the natural compound POH; NEO106, a variant of the natural compound POH; NEO212, a chimeric molecule, where POH was permanently conjugated to temozolomides; and NEO214, a chimeric molecule, where POH was permanently conjugated to rolipram. The company was incorporated in 2008 and is based in Los Angeles, California.
8335 Sunset Boulevard
Los Angeles, CA 90069
Founded in 2008
Key Executives for NeOnc Technologies, Inc.
NeOnc Technologies, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact NeOnc Technologies, Inc., please visit www.neonctech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.